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AbstrAct:
The dynamic processes of cell growth and division are under constant surveillance. 
As one of the primary “gatekeepers” of the cell, the p53 tumor suppressor plays 
a major role in sensing and responding to a variety of stressors to maintain 
cellular homeostasis. Recent studies have shown that inhibition of ribosomal 
biogenesis can activate p53 through ribosomal protein (RP)-mediated suppression 
of Mdm2 E3 ligase activity. Mutations in Mdm2 that disrupt RP binding have been 
detected  in  human  cancers;  however,  the  physiological  significance  of  the  RP-
Mdm2 interaction is not completely understood. We generated mice carrying a 
single  cysteine-to-phenylalanine  substitution  in  the  central  zinc  finger  of  Mdm2 
(Mdm2C305F) that disrupts Mdm2’s binding to RPL11 and RPL5. Despite being 
developmentally normal and maintaining an intact p53 response to DNA damage, 
the Mdm2C305F mice demonstrate a diminished p53 response to perturbations in 
ribosomal  biogenesis,  providing  the  first  in vivo evidence for an RP-Mdm2-p53 
signaling pathway. Here we review some recent studies about RP-Mdm2-p53 
signaling and speculate on the relevance of this pathway to human cancer.
IntroductIon
p53 is a tumor suppressor that has been implicated 
in regulating an assortment of cellular events including 
cell cycle arrest, apoptosis, senescence, and aging. 
p53 activation and function depend heavily on post-
translational modifications, mostly triggered by a variety 
of cellular stresses. Depending on the nature of the stress 
signal, p53 activates genes such as p21, 14-3-3 sigma, 
GADD45, and PAI1 to promote cell survival or senescence 
[1-3]. The activation of these target genes contributes 
ultimately to p53’s tumor suppression function. A 
recently revealed aspect of p53 function is its ability to 
regulate cellular metabolism. Through the activation of 
genes such as TIGAR, SCO2 and SESTRINS, p53 has 
been found to modulate mitochondrial function and 
cellular metabolism [4]. In addition, p53 has been found 
to interact with cytoplasmic ribosomes and is involved 
in translational control and ribosome biogenesis by 
influencing ribosomal RNA transcription factors and RNA 
Pol-I (RNA Polymerase-I) [5]. A recent report provides 
yet another insight into the already intricate network of 
p53 function and regulation. Mdm2, a master regulator of 
p53, has been found to modulate the p53 ribosomal stress 
response through its interaction with ribosomal proteins 
(RP) during periods of decreased and increased ribosomal 
biogenesis [6]. 
Mdm2 is an E3 ubiquitin ligase to promote p53 
ubiquitination, leading to nuclear export of p53 and 
degradation by the proteasome. Mdm2 ablation in mice 
results in early embryonic lethality due to elevated levels 
of p53-induced apoptosis, and this phenotype is reversed 
by the simultaneous deletion of p53, demonstrating 
the importance of Mdm2’s role in suppressing p53 [7-
8].  Mdm2  protein  has  three  well-defined  regions:  the 
N-terminus for p53 binding followed by a central region 
that  contains  acidic  and  zinc  finger  domains  and  a 
C-terminal RING finger domain. The RING finger region 
possesses the ubiquitin ligase activity as well as a binding 
site for the Mdm2 homologue MdmX [9]. While Mdm2 
is well recognized to negatively regulate p53 through its 
N-terminal and C-terminal domains, many other proteins Oncotarget 2011; 2:  234 - 238 235 www.impactjournals.com/oncotarget
can interact with Mdm2’s central domain in order to 
modulate its function. Most of these proteins associate 
with Mdm2 as a result of acute stimuli; among these are 
p14ARF/19ARF and the ribosomal proteins RPL5, RPL11, 
RPL23, RPS7, RPL26 and RPS3.
regulAtIon of rIbosomAl 
bIogenesIs And cell cycle 
checkpoInt. 
The regulation of ribosome biogenesis is fundamental 
for cell growth control. It involves the coordination of 
multiple steps including synthesis and processing of 
ribosomal RNA (rRNA), synthesis of ribosomal proteins 
and their import into the nucleus, assembly of ribosome 
subunits, transport of the mature 40S and 60S subunits 
to the cytoplasm, and assembly of 80S ribosome in the 
cytoplasm. The ribosomal subunits subsequently bind to 
and translate mRNAs into polypeptides. In a vigorously 
growing cell, ribosome biogenesis is a major consumer of 
cellular energy and resource. Thus, as growth conditions 
change, cells must rapidly rebalance ribosome production 
with the availability of resources [10]. Ribosome 
biogenesis requires the transcription of rRNA by RNA 
pol I [11-12] and coordinated synthesis of ribosomal 
proteins. Impaired expression of ribosomal proteins has 
been associated with various functional consequences 
including tumorigenesis as well as growth abnormalities 
in humans and mice [13-15]. Following the discovery of 
binding between RPL11 (L11) and Mdm2 [16-17], the 
observations of Bhat et al. [18] provided insights into 
the physiological role of the L11-Mdm2-p53 pathway by 
characterizing the nature of this association under growth 
inhibitory conditions triggered by serum starvation. It 
has been shown that serum starvation activates p53 and 
induces cell cycle arrest in an L11-dependent manner 
through a mechanism involving translocation of L11 from 
the nucleolus to the nucleoplasm. The model perceived 
from a myriad of in vitro data suggested that when cells 
sense nutrient-shortage stress, ribosomal proteins are 
released from the nucleolus to the nucleoplasm where 
they can bind to Mdm2 and inhibit its E3 ligase activity, 
leading to activation of p53. 
AlterAtIons In the rp-mdm2-p53 
pAthwAy And tumorIgenesIs
The  relevance  of  these  findings  was  further 
substantiated by the discovery of Mdm2 mutations in 
the region that binds to L11 in human cancers [19-20]. It 
was demonstrated that these cancer-associated mutations 
are  confined  to  the  central  zinc  finger  of  Mdm2  and 
specifically  disrupt  the  interaction  between  Mdm2  and 
L11 or L5 in vitro [21]. As a result, the Mdm2 mutants 
(e.g. Mdm2C305F) are refractory to inhibition by ribosomal 
proteins and are maintained in a p53-suppressive mode. 
in vitro, it was demonstrated that the integrity of the 
zinc  finger  is  essential  for  Mdm2  to  efficiently  induce 
degradation of p53 and itself, but it was not strictly 
required for ubiquitination of either one [18]. These data 
uncovered a novel mechanism for Mdm2 oncogenic 
activation and a new level of Mdm2-p53 regulation, 
and together with previous studies, suggest that three 
distinct modes of p53 regulation exist: phosphorylation 
of Mdm2 and p53 by various kinases induced by DNA 
damage, induction of p14ARF-/p19ARF-Mdm2 interaction 
triggered by oncogenic insults, and the induction of RP-
Mdm2 interaction triggered by signaling malfunctions in 
ribosomal biogenesis. Although it was clear, based on the 
above studies, that the RP-Mdm2-p53 pathway conveyed 
signals sensing nutrient status to ribosomal biogenesis 
and cell cycle control, it was crucial to unravel the 
physiological consequences of such interactions. Macias 
et al [6] took those findings to a physiological level by 
providing in vivo evidence for a prevailing p53 checkpoint 
mediated by RP-Mdm2 interaction. The study created a 
genetic mouse model to elucidate the in vivo physiological 
relevance of the interaction between L11 and Mdm2, and 
determined how impaired p53 function affects cell growth 
and tumor development. This knockin mouse carries a 
cysteine-to-phenylalanine mutation (Mdm2C305F) in the 
zinc finger region, preventing Mdm2-L11 binding. Under 
normal conditions, Mdm2C305F/C305F homozygous mutant 
mice showed no obvious phenotypical or developmental 
differences compared to their wild type counterparts, 
nor did they display a genetic predisposition to the 
development of spontaneous tumors. Mouse embryonic 
fibroblast  (MEF)  cells  homozygous  for  the  Mdm2C305F 
mutation displayed a normal DNA damage response to 
various DNA-damaging reagents including Doxorubicin, 
UV, γ-irradiation, as well as a high dose of Actinomycin 
D.  Whole  body  γ-irradiation  yielded  indistinguishable 
levels of p53 target gene activation and apoptosis 
between wild type and Mdm2C305F mutant groups. In 
contrast, treatment with reagents that specifically targeted 
ribosomal biogenesis confirmed that impaired L11-Mdm2 
binding results in an attenuated p53 response, thus failing 
to induce cell cycle arrest in the Mdm2C305F mutant mice. 
Altogether, it was established with this in vivo model that 
the RP-Mdm2 interaction transduces cellular stress signals 
from  ribosomal  biogenesis  specifically,  but  not  DNA 
damage, to p53. However, the role of the RP-Mdm2-p53 
pathway in tumorigenesis had yet to be determined. To 
address this question, the oncoprotein c-Myc was studied 
in conjunction with the Mdm2C305F mutation. c-Myc 
is overexpressed in numerous types of cancers and is 
known to regulate ribosomal biogenesis through direct 
transactivation of many genes involved in ribosomal 
biogenesis. In particular, L11 is a direct transcriptional 
target of c-Myc and interferes with c-Myc-dependent 
transactivation by competing with its cofactors for DNA Oncotarget 2011; 2:  234 - 238 236 www.impactjournals.com/oncotarget
binding [22]. L11 also seems to affect c-Myc expression 
levels, as knockdown of L11 increases the mRNA and 
protein levels of endogenous c-Myc [22]. Thus, the 
coordinated regulation of L11 and c-Myc may function in 
a negative feedback loop, acting as a sensor of abnormal 
ribosome biogenesis and consequently limiting c-Myc-
driven proliferation [23]. To explore whether the L11-
Mdm2-p53 pathway collaborates with c-Myc-induced 
tumorigenesis, or whether these two pathways function 
independently, Macias et al. developed compound mice 
by breeding Eµ-Myc transgenic mice into the Mdm2C305F/
C305F  background.  Eµ-Myc/Mdm2C305F/C305F compound 
mice displayed an accelerated death rate due to an early 
onset of lymphomas. Furthermore, it was clearly shown 
that in organs derived from non-tumor-bearing Eµ-Myc/
Mdm2C305F/C305F compound mice there was an increased 
level of expression of L11 and L5 compared to non-Eµ-
Myc control mice. Cellular fractionation experiments 
using splenocytes derived from these mice showed 
that c-Myc-induced L11 saturated both the nucleolar 
and nucleoplasmic fractions. Co-immunoprecipitaion 
experiments from splenic extracts showed that L11 
derived from Mdm2C305F mice was unable to associate 
with the mutant Mdm2 and, in turn, the p53 response to 
c-Myc-induced tumorigenesis was impaired in these mice 
[22]. These investigations demonstrate that the integrity 
of the RP-Mdm2-p53 pathway is crucial for protection 
against c-Myc-induced lymphomagenesis in vivo. 
p14ARF/p19ARF acts as a tumor suppressor in the p53 
pathway. It binds to Mdm2 and blocks its E3 ligase activity, 
leading to concomitant stabilization and accumulation of 
p53. The functional consequence of p19ARF’s regulation 
of p53 through inhibition of Mdm2 is evidenced by the 
ability of ectopically expressed p19ARF to restore a p53-
imposed G1 cell cycle arrest that is otherwise abrogated 
by Mdm2 [24]. Interestingly, p19ARF is required for p53 
activation from proliferative signals such as c-Myc 
activation, but not for activation in response to ultraviolet 
or ionizing radiation [25]. 
Considering the intimate connections between 
c-Myc, p19ARF, Mdm2, RP and p53, it is logical to 
question how these pathways communicate or cooperate 
in the context of tumorigenesis. Are the RP-Mdm2-p53 
and p19ARF-Mdm2-p53 pathways functioning in a linear 
or  a  parallel  fashion?  Using  mouse  embryo  fibroblast 
(MEF) cells derived from wild type, p19ARF-null, and 
Mdm2C305F/C305F mice, it was demonstrated that the p19ARF-
Mdm2-p53 pathway acts independently from the RP-
Mdm2-p53 pathway in terms of c-Myc’s induction of 
p53. Two independent approaches helped to arrive at this 
conclusion. First, transient expression of c-Myc resulted in 
a partial p53 increase in both p19ARF-null and Mdm2C305F/
C305F MEFs, indicating that each pathway contributes 
separately to c-Myc’s activation of p53. Second, ribosomal 
stress induced by a low concentration of Actinomycin D 
in p19ARF-null and wild type MEFs, but not Mdm2C305F/
C305F MEFs, led to elevated levels of both Mdm2 and p53 
as well as increased binding between Mdm2 and L11, 
indicating that p19ARF is dispensable for induction of p53 
by low-level Actinomycin D, which is known to activate 
p53 through the RP-Mdm2 pathway. Moreover, both Eµ-
Myc/Mdm2+/+ and Eµ-Myc/Mdm2C305F/C305F mice showed 
induced levels of p19ARF in tumor-bearing mice compared 
to non-tumor-bearing littermates, suggesting that p19ARF-
Mdm2-p53 signaling remains intact in the Mdm2C305F/
C305F mice. In summary, these studies established that 
figure 1: mdm2 conveys stress signals to p53 through multiple pathways. Changes in nutrient availability or treatment with 
low doses of Actinomycin D lead to nucleolar (ribosomal) stress. As a result, ribosomal proteins L5 and L11 bind to and inhibit the E3 ligase 
function of Mdm2, resulting in p53 stabilization and activation. In addition, oncogenic insults, such as aberrant expression of c-Myc, induce 
the expression of both p19ARF and ribosomal proteins. The RP-MDM2-p53 and p19ARF-Mdm2-p53 represent two parallel signaling pathways in 
response to oncogenic c-Myc stimulation.Oncotarget 2011; 2:  234 - 238 237 www.impactjournals.com/oncotarget
p19ARF is likely not required for ribosomal stress-induced 
p53 activation and that the RP-Mdm2-p53 pathway is 
an important barrier for defending against oncogenic 
c-Myc-induced tumorigenesis, independent from p19ARF-
Mdm2-p53 signaling (Figure 1). 
Through its interaction with Mdm2, p19ARF mediates 
a p53-dependent checkpoint in response to a broad range 
of oncogenic insults including elevated expression of 
c-Myc, E2F1, Ras, E1A, and v-Abl [26]. In this sense, 
it is conceivable that the L11-Mdm2-p53 signaling also 
mediates a p53-dependent checkpoint in response to 
deregulated oncogenes that promote superfluous ribosome 
biogenesis.  For  instance,  E2F1  specifically  interacts 
with and enhances rRNA promoter activity through 
two E2F1-binding sequences [27], and oncogenic Ras 
influences mTOR activity, and thus protein translation, 
by modulating the PI3K-Akt signaling cascade [26]. 
In both cases, the oncogenic activity of E2F1 and 
Ras promotes ribosomal biogenesis either directly 
or indirectly. Whether the L11-Mdm2-p53 signaling 
pathway is specific to c-Myc, or whether it is a general 
oncogenic surveillance pathway that responds to a broad 
range of deregulated oncogenes, including E2F1 and Ras, 
remains to be determined. Several reports have described 
upregulation of the ribosomal biogenesis pathway in mice 
subjected to a two-stage carcinogenesis protocol [28-
29]. Treatment of mouse skin with the genotoxic agent 
7,12-Dimethylbenz(a)anthracene (DMBA) creates Ras 
mutations, combined with serial applications of the tumor 
promoter 12-O-tetradecanoylphorbol-13-acetate (TPA) 
[30], lead to the development of mouse skin papillomas. 
With sufficient genomic instability, these treatments can 
also lead to malignant progression and development of 
squamous cell carcinomas [31-32]. Thus, using skin as a 
model, it would be valuable to test the possibility that Ras 
activation collaborates with the RP-Mdm2-p53 pathway 
to induce malignant progression and carcinogenesis. 
In addition, both Rb family proteins and p53 have been 
reported to negatively  regulate Pol-I-dependent rRNA 
transcription (reviewed by  Ruggero  and  Pandolfi  [15]). 
Can the L11-Mdm2-p53 pathway and the Rb/p53-Pol-I 
pathway intertwine in a feedback loop  to positively 
regulate each other? Studying these issues could aid in our 
understanding of how cell growth control is coordinated 
with cell cycle regulation. 
It has recently been reported that p53 regulates 
mitochondrial respiration [33]. A direct transcriptional 
target  of  p53,  SCO2,  was  identified  that  modulates 
aerobic respiration. Deregulation of SCO2 more or less 
recapitulates the Warburg Effect, a phenomenon in which 
cancer cells rely primarily on glycolysis rather than 
oxidative phosphorylation to generate energy even in the 
presence  of  sufficient  oxygen.  Interestingly,  the  study 
establishes a genetic pathway in which the inactivation 
of p53 may promote tumorigenesis by decreasing cellular 
dependence on oxygen, potentially permitting growth 
in more hypoxic environments. Thus, it is possible that 
by taking advantage of the Mdm2C305F animal model, we 
could evaluate the functional consequences of Mdm2 
mutation under ribosomal stress conditions. Evaluating 
the outcome of changes in nutrient availability through 
food deprivation, calorie restriction and exercise, and the 
impact on mitochondrial response under those metabolic 
changes, would allow us to better understand the non-
tumor suppressor, pro-survival functions of p53 as well 
as to explain why this gene is so widely conserved during 
evolution
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